DSC Investment led Illimis Therapeutics' 58 billion KRW ($42M) Series B for CNS and immune disease drug development via GAIA platform. Yohan Kim of DSC appointed to board.
Illimis Therapeutics is dedicated to translating cutting-edge science into innovative medicines for incurable diseases, particularly focusing on neurodegenerative disorders through their GAIA platform technology
Illimis Therapeutics is dedicated to translating cutting-edge science into innovative medicines for incurable diseases, particularly focusing on neurodegenerative disorders through their GAIA platform technology.